The Role of Artificial Intelligence in Heart Failure Management

Medical technology, doctor use AI robots for diagnosis, care, and increasing accuracy patient treatment in future. Medical research and development innovation technology to improve patient health.

In a recent commentary, Dr. Michelle Kittleson, a heart failure transplant cardiologist, highlights the transformative potential of artificial intelligence (AI) in heart failure (HF) management. AI, particularly through machine learning, enables advanced pattern recognition and data-driven decision-making. It shows promise in early detection, such as predicting incident HF using electronic health records, which could prompt timely interventions like echocardiograms or peptide assessments.

Heart Failure and Key Role of Cardiac Magnetic Resonance

There has been a significant shift in the understanding of heart failure caused by transthyretin cardiac amyloidosis (ATTR-CA). Once thought to be a rare condition, the adoption of nuclear imaging for diagnosis has revealed that ATTR-CA is more common in clinical practice than previously believed. This has been a crucial development as it allows for earlier identification and intervention.

First Randomized Trial Evaluates Cardiac Shockwave Therapy With Coronary Artery Bypass Graft Surgery

This study is the first randomized, sham-controlled trial to evaluate the effects of direct cardiac shockwave therapy (SWT) combined with coronary artery bypass graft surgery (CABG) in patients with reduced left ventricular function undergoing surgical revascularization. During the procedure, shockwaves were applied directly to the ischemic myocardium identified by preoperative cardiac MRI. The trial (CAST-HF; NCT03859466) involved patients with left ventricular ejection fraction (LVEF) ≤40%, who were randomly assigned to receive either direct cardiac SWT or a sham treatment in addition to CABG. The primary efficacy endpoint was the improvement in LVEF measured by cardiac MRI from baseline to 360 days.

Study Finds Empagliflozin Reduces Hospitalizations More Than Dapagliflozin in Patients With Heart Failure

A recent study compared the effects of empagliflozin and dapagliflozin on all-cause mortality and hospitalization in patients with heart failure (HF) using the TriNetX Research Collaborative Network database. Among 28,075 patients newly started on either drug, 11,077 in each group were matched for demographics and comorbidities. The primary outcome was a composite of all-cause mortality or hospitalization within one year, with secondary outcomes including individual components of the primary outcome, last measured HbA1c, and adverse effects.

Review Highlights Significant Advances and Ongoing Challenges in Heart Failure Management

A recent review by British Medical Journal researchers highlights the evolving landscape of heart failure management. The researchers analyzed studies from major databases, focusing on randomized clinical trials and cohort studies published between January 2015 and July 2023, aiming to update clinical practices that were not included in recent major heart failure guidelines.

A Remote Heart Failure Monitoring Tool: Data Presented

A biomarker-guided predictive care company, Bodyport, showed that its FDA-cleared, non-invasive technology for remote heart failure monitoring detected twice as many heart failure events when compared to current standard of care. Data were presented at the third annual Technology and Heart Failure Therapeutics conference in Boston. During the study, the congestion index correctly predicted 48 of 69 heart failure events (70%), demonstrating higher sensitivity (p<0.01) than the weight-scale standard of care. 

Heart Failure Guidelines: Question #14 With Dr. Javed Butler

Episode #281 in the CardioNerds Decipher the Guidelines Series discusses a question related to Section 9.5 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure, posed by Hirsh Elhence, a medical student from Keck School of Medicine USC and a CardioNerds intern. The question is framed around the most appropriate initial treatment for a 70-year-old woman who has been in the hospital for two weeks, with lab tests highlighting a significant rise in serum Creatinine and elevated liver enzymes. The initial answer is provided by Dr. Aman Kansal, a cardiology fellow from Duke University and a CardioNerds FIT Ambassador. A further answer is given by Dr. Javed Butler, President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health.